Summit Therapeutics PLC (SMMT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Summit Therapeutics PLC (SMMT) has a cash flow conversion efficiency ratio of -0.484x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-93.08 Million) by net assets ($192.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Summit Therapeutics PLC - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Summit Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SMMT total debt and obligations for a breakdown of total debt and financial obligations.
Summit Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Summit Therapeutics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pinnacle West Capital Corp
NYSE:PNW
|
0.092x |
|
TELECOM ITALIA ADR 1
F:TQIA
|
N/A |
|
Kerry Group
IR:KRZ
|
0.052x |
|
Dr. Reddy’s Laboratories Ltd ADR
NYSE:RDY
|
0.043x |
|
Jack Henry & Associates Inc
NASDAQ:JKHY
|
0.069x |
|
Ivanhoe Mines Ltd.
TO:IVN
|
-0.006x |
|
COVESTRO AG SP.ADR 1/2
F:1CO1
|
N/A |
|
Service Corporation International
NYSE:SCI
|
0.130x |
Annual Cash Flow Conversion Efficiency for Summit Therapeutics PLC (2003–2024)
The table below shows the annual cash flow conversion efficiency of Summit Therapeutics PLC from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see SMMT market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $388.75 Million | $-142.11 Million | -0.366x | +63.00% |
| 2023-12-31 | $77.69 Million | $-76.76 Million | -0.988x | -200.93% |
| 2022-12-31 | $126.65 Million | $-41.58 Million | -0.328x | +62.33% |
| 2021-12-31 | $83.28 Million | $-72.59 Million | -0.872x | -43.93% |
| 2020-12-31 | $79.45 Million | $-48.11 Million | -0.606x | -137.76% |
| 2019-12-31 | $61.12 Million | $-15.56 Million | -0.255x | +59.56% |
| 2018-12-31 | $55.80 Million | $-35.14 Million | -0.630x | +57.66% |
| 2017-12-31 | $13.98 Million | $-20.79 Million | -1.487x | +57.20% |
| 2016-12-31 | $-4.37 Million | $15.18 Million | -3.476x | -327.51% |
| 2015-12-31 | $30.10 Million | $-24.47 Million | -0.813x | -7.44% |
| 2014-12-31 | $22.55 Million | $-17.06 Million | -0.757x | +38.60% |
| 2013-12-31 | $7.85 Million | $-9.68 Million | -1.232x | -10.25% |
| 2012-12-31 | $4.50 Million | $-5.03 Million | -1.118x | -10.96% |
| 2011-12-31 | $3.78 Million | $-3.81 Million | -1.007x | -35.34% |
| 2010-12-31 | $5.82 Million | $-4.33 Million | -0.744x | -272.12% |
| 2009-12-31 | $13.22 Million | $-2.65 Million | -0.200x | +83.25% |
| 2008-12-31 | $12.33 Million | $-14.72 Million | -1.194x | -300.45% |
| 2007-12-31 | $54.08 Million | $-16.13 Million | -0.298x | -100.74% |
| 2006-12-31 | $40.11 Million | $-5.96 Million | -0.149x | -37.19% |
| 2005-12-31 | $23.38 Million | $-2.53 Million | -0.108x | -724.67% |
| 2004-12-31 | $26.53 Million | $-348.33K | -0.013x | -2.42% |
| 2003-12-31 | $142.31K | $-1.82K | -0.013x | -- |
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small… Read more